A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.

Overcoming disease resistance remains a challenge in R/R MM. Novel therapeutic approaches targeting MM antigens and/or enhancing immune cell function offer the potential to prolong survival and are actively being investigated in clinical trials.